Prepared remarks
Greetings, and welcome to the Nutex Health's 2026 Second Quarter 10-Q Earnings Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce Vivian Sanders, Corporate Director of Marketing. Please go ahead.
Good morning, everyone, and welcome to Nutex Health, Inc.'s Second Quarter 2026 Earnings Call. My name is Vivian Sanders, and I'm happy to serve as your moderator today. We're truly grateful for your participation and your continued interest in our company as we share the highlights of another exceptional quarter. Please note that this call is being recorded for future reference. Joining me this morning are the key leaders driving Nutex Health forward. Our Chairman and CEO, Dr. Tom Vo; our Chief Financial Officer, Jon Bates; our President, Dr. Warren Hosseinion; and our Chief Operating Officer, Wes Bamburg. Together, they'll provide prepared remarks to give you a comprehensive view of our performance, strategies and vision, after which we'll open the floor for your questions. Before I turn things over to Dr. Vo, I'd like to take a moment to address a few important points. Today's discussion may include forward-looking statements, which reflect management's current expectations about our future performance.
These statements are based on what we know today, but they are subject to risks, uncertainties and other factors that could cause our actual results to differ from what we'll share. For a deeper dive into these forward-looking statements and the factors that may influence them, I encourage you to review the press release and Form 10-Q filed earlier this week as well as our various SEC filings. You'll find all the details there. Additionally, we may reference non-GAAP financial measures such as adjusted EBITDA during the call. For those interested in how these metrics reconcile to GAAP standards, please refer to the press release and Form 10-Q, where that information is included. With those housekeeping items out of the way, it's my pleasure to hand the call over to Dr. Tom Vo, our Founder and Chief Executive Officer. Dr. Tom Vo, the floor is yours.
Thank you, Vivian, and good morning, everyone. I am happy to join you today to review Nutex Health's second quarter 2026 results. It was an active quarter, marked by strong financial results, important reimbursement developments and continued progress on our growth pipeline, both internally with hospital volume and acuity as well as new pipeline developments. Let me begin with our first 6 months financial and operational performance. For the first 2 quarters of 2026, total revenue reached $427.2 million, a slight 6% decrease from $455.8 million for the same period in 2025. This is primarily due to timing from accrual to cash collections, as Jon will further explain. Net income attributable to Nutex increased to $112.6 million for the first 2 quarters of 2026, a 3,100% increase from $3.5 million for the same period in 2025. Adjusted EBITDA increased 2% from $144.4 million to $147.5 million for the first half of 2026.
On the volume side, for the first 2 quarters of 2026, our hospitals recorded 99,700 total patient visits, up 6.2% from 93,800 during the same period in 2025. Same-hospital growth was 3.4% in the first 6 months of 2026. Notably, same-hospital visits grew 6.3% in the second quarter of 2026, reflecting strong operational execution and the impact of our internal investment over the past year. On the balance sheet, net long-term debt increased from $29.2 million at December 31, 2025, to $31.1 million at the end of Q2 2026, still very low relative to our revenue and expansion pace. Cash on hand grew to $207.1 million as of June 30, 2026, up from $185.9 million at year-end 2025. Net cash from operating activity was $109.7 million for the first 2 quarters of 2026 compared to $78.2 million in 2025, a 40% increase. Our strong first half performance was driven by several factors: continued growth in inpatient volume and acuity due to renewed internal initiatives and investments, lower earn-out expenses as most legacy facilities that were in development as of 2022 have vested, reduced arbitration-related costs following a catch-up reconciliation and sustained collection strength from both our internal and external revenue cycle teams.
In addition, we are seeing more stabilization of revenue this year compared to this time last year. Jon will also discuss these details in his report. On the reimbursement side, the quarter was highly active with important provider wins in federal courts as well as the final federal ruling improving the administration of the IDR process. So let us start on the legal side. During the first half of 2026, courts in California, Florida, Pennsylvania, Texas, Connecticut and Georgia all issued decisions reinforcing the finality of the IDR awards and limiting insurers' ability to challenge arbitration outcomes in court. The court further indicated that insurers' objections to the high IDR loss rates are matters for Congress, not the federal courts. For Nutex, these rulings are important because they support the integrity of the IDR process and provide additional precedent for a fair federal dispute resolution system.
In fact, in the Georgia ruling, the judge stated, "It is highly improbable to infer from these facts that there is a vast conspiracy of providers and IDREs that have conspired to defraud the plaintiff of millions of dollars in thousands of IDR NSA proceedings over many years." He further stated, "It is highly possible to infer that the plaintiff engages in a consistent practice of submitting lowball offers to out-of-network providers in an effort to maximize its profits." Insurers have largely executed this low provider payment strategy very successfully as reflected in the record profitability during the first half of 2026, where profits were in the billions. And while we are very happy for the financial successes of the insurance companies, our position is very simple. Nutex seeks fair market-based reimbursement for comparable care. Patients treated at our facilities should be reimbursed consistent with the cost of similar services delivered at comparable facilities.
A functional IDR process promotes fair free market competition, protects access to high-quality care, and reduces unnecessary disputes. If insurers pay appropriate rates at the outset, fewer claims would need to proceed through the IDR process. On the regulatory side, on May 28 of this year, CMS and other federal agencies released the final IDR rules, which focuses on improving the efficiency and transparency of the IDR process without changing the core reimbursement framework. Key improvements include better disclosures from insurers to prevent and limit future ineligible charts, a more efficient electronic portal to encourage open negotiations, lower administrative fees from $115 to $15, expanded batching for certain claims and a shorter cooling off period. Overall, we view the final rule as constructive for providers and for Nutex. Congress and the Centers for Medicare and Medicaid Services, or CMS, recognize that the independent dispute resolution process remains the only available meaningful mechanism through which providers may contest inadequate insurer reimbursement.
In its absence and without the IDR process, insurers would have unchecked pricing authority and a monopoly position within the market. Lastly, the final rule reflects CMS' intent to create a more streamlined, user-friendly system that providers and payers can use effectively when needed. We believe that this underscores CMS' view that the IDR process will remain in place for the foreseeable future. On the vendor front, earlier this month, we announced an amendment with HaloMD that shifts the fee structure to pay on a collective basis, retroactive to the original agreement. This helped reduce IDR costs in the quarter and gives us more flexibility to manage dispute resolution services going forward. Combine this with a lower CMS IDR cost, this amendment will result in lower total arbitration-related costs in the future. In addition, we now have additional options to utilize other arbitrator vendors going forward if necessary.
Turning to growth. We remain very excited about our hospital development pipeline and opportunities ahead. We have started internalizing the real estate development capabilities, giving us better control over timelines, cost and scalability. Our strategy is not to be a long-term real estate owner. We plan to develop facilities, stabilize operations and then monetize the real estate through sale-leaseback transactions upon hospital opening or stabilization. Looking ahead, our current pipeline in 2026 includes West Little Rock, Arkansas; San Antonio, Texas; and Jacksonville, Florida. All three are expected to open in the third and fourth quarter of 2026. For 2027, our pipeline includes new hospital developments in South and Central and East Florida as well as Oklahoma. Notably, two of these projects are expected to be initially owned and developed by Nutex. Beyond 2027, we have already approved additional Nutex-owned and Nutex-led projects in Idaho, Florida, Pennsylvania, Ohio and Arkansas.
As a public company, we are very fortunate to have the ability to continue growing through de novo hospital developments. Because building large-scale hospitals presents significant challenges and costs, larger healthcare systems are often limited to volume growth as the primary expansion strategy. Nutex, on the other hand, can grow both internally as well as de novo by advancing a focused national pipeline of smaller, scalable facilities. Together, these two approaches provide a clear road map for long-term growth and strong shareholder value creation. Operationally, Wes will provide more details, but we remain focused on increasing volume, expanding service lines and growing appropriate observation and inpatient care within our hospitals. Patients often tell us they prefer to remain in our hospital rather than be transferred to another hospital for a higher level of care. We also continue to invest in technology, diagnostic capabilities and differentiated patient service, which are key elements of the Nutex model.
Patient satisfaction remains a key strength of our model as reflected in our continued recognition through multiple hospital awards as well as our reputation as a trusted hospital of choice for healthcare providers and their families in the communities we serve. So with that, I'll turn the call over to Jon Bates, our Chief Financial Officer, to walk through the financials in more detail. Jon?
Thanks, Tom. And good morning, everyone. Let me go through some of the details on the financials for Nutex Health's second quarter and first half of 2026. Another strong period where our earnings are strong and our cash flow continues to build as we plan for three future openings later this year and continue to prove out our growth model year-over-year. Now Tom has given you a little bit of the big picture, and I'll attempt to provide a little more detail. I'm going to start with the three months ended June 30, 2026, compared to the three months ended June 30, 2025. So total revenue for Q2 of '26 decreased 13.6% to $210.8 million compared to $244 million for the same period in '25. Of the total revenue decrease, hospital division revenue decreased 14.6% to $201.9 million from $236.3 million, while same hospitals decreased their revenue by 12.1% for the second quarter of 2026 compared to the same period in 2025.
Now the main reason for the revenue decrease period-over-period was due to the larger positive increase in revenue in the 2025 period as the IDR process began showing stronger realization of revenue in the first half of 2025 with us experiencing early success with the IDR process. If you recall, the revenue per visit, which does include both the ER and the inpatient services back during the second quarter of 2025 was approximately $5,185 per visit. While the cumulative net revenue per visit from when we started the IDR process in July of 2024 through June of 2025 was closer to $4,200 a visit, which is much more in line with what we have continued to see since then and into 2026. Now revenue per visit in Q2 of '25 was positively impacted by adjustments to our collection percentage from 65% at the end of December 31, 2024, up to 75% by June 30, 2025. And this positive adjustment was a result of additional historical collection history as it was being recognized in early 2025.
As the historical collection percentage leveled out to the current average of just over 80%, fewer adjustments have been recognized in 2026. Now this helps explain why current revenue per visit is more in line with the historical average measured from the start of the IDR process. And if there are no significant fluctuations in our collection percentage and other key metrics used to record revenue moving forward, we would expect the revenue per visit metric to remain similar. Hospital Division visits increased by 9.6% or 4,389 visits to 49,962 visits in quarter 2 of 2026 versus 45,573 visits in the same period in '25, with the same hospital visits growing at 6.3% over the same period, as Tom indicated earlier. With regard to the Population Health division, it had revenue growth of approximately 16% to $8.9 million for quarter 2 of '26 versus $7.7 million for the same period in 2025. Now in addition to the visit growth noted above, facility corporate level costs also showed improvement for the second quarter of '26 relative to the same period in '25.
Total facility level operating costs and expenses decreased $49.6 million during the period, representing 33% or $69.5 million of total revenue for Q2 of '26 versus 48.8% or $119.1 million for the same period in 2025. Now of the $49.6 million decrease for the period, approximately $52 million of the decrease was reflected within our contract services line and resulted from two major positive items that took place in the second quarter of 2026. The first item was the impact from the federal IDR operations final rule that was signed in May of 2026, which reduced the CMS nonrefundable administrative fee from $115 to $15 per party per dispute initiated on or after June 11, 2026. And this contributed to about $4.3 million of this total decrease. The other major item was the June 2026 amendment we negotiated to our original HaloMD contract that was signed in May of 2024. Among several other positive changes in this amendment, two of the larger items were, number one, it transitioned the applicable fee payment structure to a pay-on-collected basis rather than payment being due upon award determination with it being retroactive to the effective date of the original agreement in 2024, and this contributed about $38.4 million of that total decrease.
Secondly, it favorably amended the service fee structure applicable to various federal and state net settlement amounts obtained on or after July 1, 2026. And this contributed around $9.6 million of the total decrease. One last thing was the contract renegotiation provided the company with the right to perform dispute resolution services either in-house or through the engagement of another third-party vendor or service provider with respect to certain future hospital facilities, which Tom indicated before. Now regarding the contract services, based upon current expectations, we anticipate the CMS fee rate reduction and the amendment to the Halo contract will lead to approximately 25% to 30% decrease in our historical normalized costs in future periods, assuming our current IDR metrics continue. Because the pay-on-collection basis is our new reality, we will not have to record 100% of the IDR costs on every potential legal determination win, as we will now be only accruing costs using a similar collection percentage that we use for our accrual of revenue.
Plus, we were able to get this change done retroactive to when we signed the original agreement in 2024. So we believe we will better match our costs for this to the corresponding revenue we record, which should make the analysis much easier in the future periods. Now regarding arbitration-related revenue, we have continued to submit between 50% to 60% of our claims through the IDR process. And when an award determination is made, we currently prevail in over 85% of those determinations, and we currently have an average collection rate of over 80% of determination wins. Moving on, talk a little bit about stock-based compensation for the three months ended June 2026. It was $2.9 million compared to $78.7 million of expense for the same period in 2025, which was a $75.9 million decrease in Q2 of 2026. Currently, there are only two facilities that are part of the major expense that goes in this line item with both of them completing their earn-out period in the fourth quarter of 2026.
Gross profit for the three months ended June 30, 2026, was $141.3 million or 67% of total revenue as compared to $124.9 million or 51.2% of total revenue in the same period in 2025, a 15.8% increase for the three months ended June 30, 2026 versus 2025. From a corporate and other cost perspective, the general and administrative expenses as a percentage of total revenue for the three months ended June of '26 increased to 7.9% or $16.7 million from 5.1% or $12.5 million for the same period in 2025. Operating income for the three months ended June 30 of '26 was $121.7 million compared to $33.7 million for the same period in '25, which is an increase of $88 million. Net income attributable to Nutex Health was $65.8 million for 2026 compared to a net loss of $17.7 million for the 2025 period, which was an increase of $83.5 million. Adjusted EBITDA attributable to Nutex increased $18.4 million or 25.7% from $71.6 million in Q2 of '25 to $90 million in Q2 of '26.
So now let's move on and talk a little bit about the six-month period ended June 30 compared to the six months of June of '25. Total revenue for the first six months of '26 decreased 6.3% to $427.2 million compared to $455.8 million for the same period in '25. Of the revenue decrease, hospital division revenue decreased 7% to $409.4 million from $440.2 million, while same hospitals decreased their revenue by 6% for the first six months of '26 compared to the same period in '25. As discussed earlier in the second quarter explanation for the decrease in revenue for the period, the main reason for the revenue decrease period-over-period was due to the larger positive increase in revenue in the 2025 period as the IDR process began showing stronger realization of revenue in the first half of 2025, with us experiencing early success in the IDR process. From a hospital division visit perspective, it increased by 6.2% or 5,862 visits to 99,704 visits in the first six months of 2026 versus 93,842 visits in the same period in 2025, with same hospital visits growing at 3.4% over the same period.
With regard to the Population Health division, it had revenue growth of approximately 15% to $17.8 million for the first six months of '26 versus $15.5 million for the same period in '25. Now in addition to the visit growth noted above, facility and corporate level costs also showed improvement for the first half of '26 relative to 2025. Total facility level operating expenses decreased $18.3 million during the period, representing 45.5% or $194.2 million of total revenue for the first six months of 2026 versus 46.6% or $212.5 million for the same period in '25. And as discussed, for the second quarter of 2026, similarly, the main reason for most of the overall decrease in this line was due to the contract services decrease during the period, primarily resulting from the reduction in the CMS fee and the impact from the amendment to the HaloMD contract that we signed in the second quarter of 2026.
Moving on to the stock-based compensation. Again, for the six months ended June of '26, it was a $1 million gain compared to $106.4 million expense for the same period in 2025, which was a $107.4 million decrease in costs comparably in 2026. Now we did finalize one earn-out at March 31, 2026, as we talked in our first quarter call, and we have two more facilities currently in their measurement periods with both of them completing their measurement period in the fourth quarter of 2026. The gross profit for the six months ended June 30, 2026, was $233 million or 54.5% of total revenue as compared to $243.3 million or 53.4% of total revenue for the same period in '25, a 1.2% increase for the six months ended June of '26. From a corporate and other cost perspective, the G&A expenses as a percentage of total revenue for the six months ended June of '26 increased to 7.3% or $31.1 million from 4.9% or $22.5 million for the same period in 2025.
Operating income for the six months ended June 30, 2026, was $203 million compared to $114.3 million for the same period in 2025, which was an increase of $88.6 million. Net income attributable to Nutex Health, Inc. was $112 million for 2026 compared to only $3.5 million for 2025, an increase of $109.1 million. And adjusted EBITDA attributable to Nutex increased $3.1 million or 2.2% from $144.4 million for the six months ended June 30, '25 to $147.5 million for the same period in 2026. Now looking at our balance sheet continues to remain very strong with cash and cash equivalents at June 30, 2026 to $205.2 million, up $19.6 million or 10.6% from $185.6 million at December 31, 2025. Additionally, accounts receivable increased by $32 million to $351.7 million at June 30 of '26 from $319.4 million at December 31 of '25. We had another strong collection quarter, which provides us continued confidence in this increase.
Regarding cash flow, net income from operating activities increased by $31.5 million for the six months ended June 26 to $109.7 million as compared to $78.2 million for the same period in '25. And Tom talked about this earlier, but on the liability side, our total bank and equipment type debt decreased by $3.6 million to $39.9 million at June 30, 2026, from $43.5 million at December 31, 2025, with the majority of this debt related to equipment loans at our hospitals for such items as MRIs, X-rays, ultrasounds and CT scans. With all that said, our balance sheet remains very solid, and we provided our company the flexibility to execute on our growth plan in 2026 and beyond.
Thank you, Jon, and good morning, everyone. It's great to be with you today to discuss how Nutex Health is advancing population health management. In the first half of 2026, we continue to make strides in this area. This morning, I would like to again focus on our strategy and our upcoming goals. Let's start with where we are today. Our Population Health Management division now oversees a diverse group of almost 40,000 patients across our platform, including a mix of Medicare Advantage, commercial and Medicaid managed care members. Revenue for the division was up 15% for the six months ended June 30, 2026, from the same period in 2025. Each of our IPAs in Southern California, Houston and Phoenix were profitable for the six months ended June 30, 2026, while our IPA in South Florida was slightly cash flow negative for the same period. Our new IPAs in Dallas and San Antonio are still contracting with primary care physicians and specialists and will begin enrolling patients in 2027.
Our overarching strategy revolves around physician networks. Our IPAs, or independent physician associations, are comprised of networks of contracted and credentialed primary care physicians and specialists located around our facilities. Building strong partnerships with local doctors is critical. By forming these IPAs, we are building awareness of our hospitals among the local community doctors and their patients. Why do physicians join our IPAs? We offer these physicians ownership in our IPAs. They can also participate on the Board and committees of the group. We offer them the ability to get on the staff of our hospitals so they can admit and follow patients. We also incentivize the physicians to achieve high-quality metrics. We believe that over time, these relationships will not only increase the volume of both IPA and non-IPA patients to our hospitals, but also create a web of care that's seamless for patients.
Our vision is that our hospitals and IPAs will work hand-in-hand to amplify our reach and effectiveness. We are fostering collaboration, sharing best practices and ensuring every provider is aligned with our patient-first culture. We're growing our IPA strategically, focusing on areas near our hospitals to leverage existing relationships and infrastructure.
Thank you, Warren, and good morning, everyone. I'll focus my comments on our operational performance during the second quarter, including patient volume growth, service line expansion and patient experience. Our hospitals continue to see demand across the markets we serve. As previously mentioned, during the quarter, we recorded nearly 50,000 patient visits, an increase of 9.6% compared to the prior year, while same hospital visits increased 6.3%. For the six months of 2026, total hospital visits increased 6.2% to nearly 100,000 patients served across the enterprise. These results reflect continued growth across both our newer and more mature facilities and demonstrate the ongoing strength of our model. We also continue to expand patient access and increase our ability to care for more patients within our hospitals. As facilities mature, we're able to offer a broader range of services, retain more patients locally and further strengthen our continuity of care within our communities.
During the quarter, we also made progress on service line expansion, including the launch of endoscopy services. This will allow us to provide critically needed services to the communities we serve, such as colonoscopies and diagnostic EGDs. As we evaluate performance and demand, we see opportunities to expand additional service lines across our facilities over time. As Tom discussed earlier, we also remain focused on supporting growth across our development pipeline. With several facilities expected to open later this year, we continue to leverage the infrastructure, experience and the operating playbook developed across our existing network to efficiently ramp new hospitals and support consistent execution from day one. Patient satisfaction remains a key strength during the quarter with our hospitals maintaining an average Google rating of 4.8 stars across more than 2,300 reviews. We believe those results reflect the commitment of our physicians, nurses and staff to delivering high-quality patient experience every day.
Workforce stability also remains a competitive advantage. Employee turnover was just 6.8% during the first six months of 2026, significantly below published hospital industry benchmarks, supporting consistent execution and high-quality patient care across our network. From a cost management perspective, we remain disciplined as volumes grew, maintaining focus on staffing efficiency, resource utilization and operational standardization. We believe our ability to combine growth with operational discipline continues to be an important differentiator as we scale the organization. Overall, the second quarter reflected continued operational momentum across the enterprise. We delivered strong volume growth, expanded clinical capabilities, maintained excellent patient satisfaction and continue to position the organization for future growth through both service line expansion and our new hospital development. Thank you, everyone, and I'll turn the call back over to Vivian.
Thank you, Wes, and team for those updates. I will now turn it over to our operator, who will begin the Q&A portion of the call.
Questions and answers
Our first question is from Anderson Schock with B. Riley Securities.
So previously, the arbitration costs were expected to run about 25% of arbitration-related revenue. I guess excluding the credit, what did this look like in the second quarter? And how should we think about the new go-forward rate after the May IDR final ruling and the renegotiated HaloMD agreement?
Anderson, yes, great question. If you think about it from the standpoint of the way we look at it, first of all, we talk about contract services and how that looks. And you talked about that 25% in the past, if we're just talking about specifically arbitration. So normally, it was a range in that mid-24% to 25%, 26% in the past. Now currently, as we move forward, you should expect that to be just that specific piece, probably down more into the high teens to low 20s, comparatively. So on the overall contract services rate reduction, as we talked about, it should be more into the 25% to 30% range. That's on overall contract services. But arbitration, you would see that correspondingly work its way down.
Okay. Got it. And then is the second quarter revenue per visit a fair steady state run rate? Or should this further normalize in the back half as the IDR catch-up rolls off the 2025 base?
So as we talked about in the past, if you look back, the cumulative rough estimate of where reimbursement has been since we started the process overall was really in that $4,000 to $4,200 range. And that's remained pretty consistent. So even for this period, yes, I think it's in line. There'll be some variability up and down. As we continue to have more inpatients, which I think is one of the improvements we're starting to see, you'll see a little bit higher in that area. But I think in the range that we've seen cumulatively since we started the process through June of '26, which is very similar to what we have in the quarter and first six months of '26, I think, is a fair number to be looking at as you move forward for now.
Okay. Got it. And then with the opening cadence for the next two years kind of at the higher end of your historic range and your new self-financing strategy funding the opening of half these next year, should we expect an increase from the historic range of three to five hospital openings per year in the future?
Anderson, I could take that question. No, we're still basically focusing on three to five hospitals per year. That has not changed yet at this point. Obviously, we will continue to evaluate new locations. As you know, we get requests to open these hospitals on a weekly basis. And so as we discuss internally and in accordance with our financials, we will reevaluate that three to five hospitals per year.
Our next question is from Ben Haynor with Lake Street Capital Markets.
First off for me, with these recent court cases that have gone in the right direction for you guys, do you see any change to insurer behavior with regards to collection rates based upon those?
Ben, I can take this and maybe Jon can chime in. So far, it's pretty much steady state from an insurance company payment perspective. We are seeing more commission to go in contract with health insurance companies. The rates are slowly creeping up, but it's still nowhere near where we should be.
Okay. So does that also imply that QPAs have come up a little bit and QPA multiples coming down or no?
So far, we have not seen a drastic change at this point. QPA is still relatively low. Hence, our submission rate of roughly 60%.
Okay. That makes sense. And then I guess on the submission rate, with the lower $15 fee, kind of the newer HaloMD rate and terms, do you see yourselves starting to challenge some of the ones that may have previously been considered marginal or maybe good enough?
Yes, I can talk about that. At the end of the day, the reduced fee is helpful and it lowers the barrier to entry. We've looked at that difference. There are a few that we might now take through the process that risk-wise we might not have before. But I think generally, we'll keep a similar cadence and just watch for opportunities in those situations where we might go in on some that we haven't in the past. I don't think it will be a material change for us, though it might be for some other providers.
Our next question is from Thomas McGovern with Maxim Group.
So a couple of my questions were already touched on, but I do want to piggyback off of the last question regarding the insurer behavior based on these court cases and the changing regulation around arbitration. So it sounds like maybe there's some progress on that front, but it's been pretty slow. I'm just curious from your strategic perspective, are you guys going to be proactively pursuing in-network agreements with payers? Or are you going to focus on your business and continue operating and wait for payers to come to the table with you?
Thomas, the answer is we are always looking to go in-network with the insurance company. We're continuing to evaluate any contracts that come in. As I mentioned earlier, the rates have come up a little bit over the past quarter or so, but still nowhere near where we need to be.
Understood. And then looking at the patient volume and acuity growth that you guys commented on in your prepared remarks, I just want to understand a little bit better what drove that success in the quarter? And then how should we look at acuity, like as you are adding service line items and increasing in-house patient visits, how should we expect the revenue per patient to trend over time?
I can answer that. It's a two-part explanation. Over the past couple of quarters, we've increased investment in internal processes by adding business development personnel, using AI, engaging more physicians and leveraging the IPA network to increase volume. Once we get patients through the door, our focus is on keeping the patients in the hospital to increase inpatient volume. As you know, inpatient pays significantly better than ER payments. If we continue to execute on that, revenue per patient should increase because we would have more inpatient visits in the future. On top of that, as Wes mentioned, we're starting to do more procedures; for example, we're offering colonoscopy services in one of our hospitals and evaluating other procedures based on community needs.
Tom covered it well. We are centralizing and focusing on business development at an enterprise level and looking across all hospitals to identify opportunities. That may differ by location. We're evaluating those opportunities and bringing services in-house where appropriate. Secondarily, we continue to add capabilities to take care of sicker patients, which increases inpatient volumes and has a positive net impact overall.
Understood. And then finally for me, I just want to unpack this HaloMD renegotiation of the amendment to your agreement just a bit. High level, what drove that conversation? What made you come to the table with them and say, hey, we need to reevaluate these terms? And under what circumstances would you exercise your newly gained optionality to pursue arbitration claims in-house or use a third party for some of these newer facilities?
We started arbitration in July 2024 but before that, arbitration was still in its infancy. When we signed the original agreement in early 2024, we had limited data and limited infrastructure. Since then, the IDR process has evolved significantly and we have much more information. HaloMD was and remains a leading vendor in this space. Given how much we've learned over the last two years, it was an appropriate time to renegotiate the contract based on what we know now versus what we knew in early 2024.
I'll add to that. HaloMD is a great partner and they've done a solid job. We've both learned a lot over the last two-plus years; the industry has more data and more participants now. We looked for ways to clarify the original agreement and make changes that make sense for both sides. The renegotiation gives us flexibility to either use a third party, do it ourselves for select facilities, or keep working with Halo. It's a win-win that puts us in a better position to pivot if things change. Remember, we don't use IDR for every visit, and as we get some better contracts and improved payer payments over time, we expect to use IDR for fewer claims.
Our next question is from Bill Sutherland with The Benchmark Company.
Great progress. Jon, just to follow up on that question somewhat. Would you ballpark kind of the numbers or the percentage of things going into negotiation that are being handled in negotiation? I guess what I'm trying to ask is, has there been some movement on that front that's measurable?
Bill, first, in the process of going through IDR, submissions include a discussion with the payer about in-network negotiation. We always express interest in negotiating and attempt settlement before arbitration. We have continual communication with multiple payers and have had some successful settlements. More often than not, however, payers still resist providing fair and reasonable payment, so many matters proceed to arbitration. It's an active effort and we expect to continue increasing negotiated outcomes over time, but it's a gradual process.
So nothing's changed materially in terms of the percentage that goes to IDR?
Yes, that's fair. It has improved slightly, but it's a modest improvement. We also expect regulatory communications to support more settlements over time, but it will take time.
And has your percentage of revenue that's in-network changed either?
There's been a slight increase in in-network revenue, but it's not material.
Bill, I want to reiterate one point: while we are out-of-network for many contracts, our model allows us to operate successfully out-of-network. The No Surprises Act allows emergency patients to go to any hospital and still expect payment consistent with in-network rates in certain circumstances. We evaluate every contract that comes in, and if terms are not acceptable, we can remain out-of-network and use the IDR process as a tool to obtain fair reimbursement. Also, being in-network doesn't guarantee all issues are resolved; even large hospital systems periodically have in-network disputes with payers. So being in-network is not a panacea.
And then one last question on seasonality: patient visits were pretty flat sequentially. Remind us about the seasonality as we think about patient visits going forward.
Typically, the second and third quarters are the lowest and the fourth quarter and the first quarter are the highest because of the colder season and flu season.
There are no further questions at this time. I'd like to hand the floor back over to Vivian Sanders for any closing comments.
Thank you all for those valuable questions and answers. For all of those joining us today, if you have more questions, e-mail us at investors@nutexhealth.com, and we'll get back to you promptly. On behalf of the Nutex management team, thank you all for joining us for our second quarter 2026 earnings call. We've covered a lot — growth, strategy, challenges and our vision — and we appreciate your time and interest. A recording of this call will be available on our website for a limited time. So feel free to revisit it. Take care, everyone, and we look forward to keeping you updated on our journey.
This concludes today's conference call. You may disconnect your lines at this time. Thank you again for your participation.